Yiping Zhang
Hohai University(CN)Yangtze University(CN)Guizhou University(CN)Chinese Academy of Medical Sciences & Peking Union Medical College(CN)Norton Healthcare(US)Ministry of Natural Resources(CN)National Health and Family Planning Commission(CN)Xishuangbanna Tropical Botanical Garden(CN)Chinese National Human Genome Center(CN)China University of Geosciences(CN)University of Jinan(CN)Key Laboratory of Guangdong Province(CN)Yangtze River Delta Physics Research Center (China)(CN)Xichang University(CN)Zhejiang Lab(CN)Yunnan Academy of Agricultural Sciences(CN)China National Chemical Information Centre (China)(CN)Zhejiang Institute of Mechanical and Electrical Engineering(CN)Tianjin Municipal Research Institute for Family Planning(CN)Institute of Mining(RU)Fujian Institute of Oceanography(CN)Zhejiang University of Technology(CN)Henan Normal University(CN)Zhejiang University(CN)Lanzhou University(CN)South China University of Technology(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Urban Stormwater Management Solutions, Crystallization and Solubility Studies, X-ray Diffraction in Crystallography
Most-Cited Works
- → Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial(2020)492 cited
- → Basic principles in starch multi-scale structuration to mitigate digestibility: A review(2021)323 cited
- → Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial(2021)300 cited
- → Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial(2020)251 cited
- → EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study(2017)150 cited